Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Brain & Behavior Research Foundation to honor 7 scientists for exceptional research on mental health

The Brain & Behavior Research Foundation celebrates the transformative power of neuroscience and psychiatric research to improve the lives of those with mental illness. Seven exceptional scientists will be honored at the Annual National Awards Dinner at the Pierre Hotel in New York City on Friday, October 25, 2013.

7 Oct 2013

Parkinsonism predicts schizophrenia cognitive course

Parkinsonism is common in patients with first-episode psychosis and is predictive of cognitive impairment, say researchers.

3 Oct 2013

Carbonyl stress suggests strategy for treatment-resistant schizophrenia

Patients with schizophrenia who have enhanced carbonyl stress have clinical features associated with treatment resistance, say researchers.

1 Oct 2013

Cogstate test shows effective treatment option for schizophrenia

Medical technology company Cogstate continues to strengthen its position as an essential partner for measuring cognition in important studies around the world, with results from a schizophrenia study using Cogstate's test published in a major scientific journal.

27 Sep 2013

Study: Antidepressant drugs prove to be effective against SCLC patients

A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

27 Sep 2013

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Omeros Corporation today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

19 Sep 2013

Neuropsychologic decline precedes schizophrenia onset

Researchers have confirmed that neuropsychologic functioning declines in individuals with schizophrenia from before to after illness onset.

18 Sep 2013

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV).

17 Sep 2013

New behavioral therapy improves antidepressant treatment of OCD

NIMH grantees have demonstrated that a form of behavioral therapy can augment antidepressant treatment of obsessive compulsive disorder (OCD) better than an antipsychotic.

13 Sep 2013

Psychiatrist documents how schizophrenia impacts brain tissue

It's hard to fully understand a mental disease like schizophrenia without peering into the human brain. Now, a study by University of Iowa psychiatry professor Nancy Andreasen uses brain scans to document how schizophrenia impacts brain tissue as well as the effects of anti-psychotic drugs on those who have relapses.

12 Sep 2013

Negative symptom clue to smoking in schizophrenia patients

Patients with schizophrenia may have a preponderance to cigarette smoking because it reduces negative symptom severity, researchers report.

5 Sep 2013

Increased mortality in schizophrenia ‘not attributable to drug therapy’

The increased mortality risk observed among patients with severe psychiatric illness, including schizophrenia, does not seem to be attributable to use of psychopharmacologic therapy, study findings indicate.

4 Sep 2013

Negative symptoms ‘key to recovery’ in first-episode psychosis

The severity of negative symptoms in people with first-episode psychosis is a strong determinant of subsequent recovery, a long-term study has shown.

29 Aug 2013

Inflammatory status upregulated in first-episode schizophrenia

Patients with first-episode schizophrenia exhibit upregulation of key proinflammatory molecules, study findings show.

28 Aug 2013

Use of antipsychotics down among nursing home residents

A two-year effort by the federal government and the nursing-home industry has reduced the use of powerful antipsychotic drugs among elderly nursing-home residents, but the decline fell short of the program's goal, according to U.S. officials (Lagnado, 8/26).

28 Aug 2013

First Edition: August 27, 2013

Today's headlines include reports regarding the gathering storm as the White House and GOP lawmakers continue to hold firm in their positions regarding the looming debt limit. President Barack Obama says he won't negotiate while some Republicans are pushing for to defund, or at least delay, the health law's implementation.

27 Aug 2013

Antipsychotic drug not effective in treating delirium in critically ill patients

Haloperidol, an antipsychotic drug used in many hospitals to treat delirium in critically ill patients, is no more effective than placebo in reducing the number of days that critically ill patients spend either delirious or in a coma, according to new research published in The Lancet Respiratory Medicine.

22 Aug 2013